.png)
We figure out why drugs fail before clinical trials even start.
Find out more
A drug's journey from the bloodstream to a tumour is a long, winding one.
It's a journey filled with traps, distractions, and barriers (i.e., the tumour microenvironment) all brought about by the tumour to prevent the drug from killing it.
Each tumour is different so it’s difficult to predict the strategies it will use.
This is why only about 12% of solid tumour patients respond to immunotherapy.
But, there's a solution.
TMEmic | A next-generation in vitro model: the most accurate model of the tumour microenvironment for solid tumours.
Together, we combine proprietary material formulations, sensors, and a comprehensive bioinformatics workflow, forming our drug-development toolshed, to understand why some cancers resist the most advanced approaches to treatment.
In doing so, we uncover ways to help drugs succeed in their journey from the bloodstream to a tumour.
.png)
.svg){kind=small}